Spiro I J, Wang C C, Montgomery W W
Department of Radiation Oncology, Massachusetts General Hospital Cancer Center, Boston.
Cancer. 1993 May 1;71(9):2699-705. doi: 10.1002/1097-0142(19930501)71:9<2699::aid-cncr2820710902>3.0.co;2-t.
The authors retrospectively studied 62 patients with malignant parotid tumors, treated by combined surgery and radiation therapy between 1975 and 1989. No patients were lost to follow-up, and all living patients were interviewed. The median follow-up time was 66 months.
Among the 62 patients, there were five isolated local failures. Distant failure was observed in 11 patients. Neck failure was uncommon except in patients with advanced neck disease on presentation. The actuarial 5-year and 10-year local control rates were 95% and 84%, respectively. The corresponding actuarial disease-free survival (DFS) rates were 77% and 65%, respectively. Patients with larger tumors, recurrent disease, or involvement of the facial nerve tended to have lower DFS rates. No statistically significant differences were observed for patients treated with once-daily versus twice-daily radiation therapy fractionation schemes.
Treatment was well tolerated, and severe treatment sequelae were uncommon. In summary, surgery in combination with radiation therapy is highly efficacious in controlling malignant tumors of the parotid gland.
作者回顾性研究了1975年至1989年间接受手术联合放射治疗的62例腮腺恶性肿瘤患者。无一例患者失访，所有在世患者均接受了访谈。中位随访时间为66个月。
62例患者中，有5例出现孤立性局部复发。11例患者出现远处复发。颈部复发不常见，除非初诊时颈部病变已处于晚期。5年和10年的精算局部控制率分别为95%和84%。相应的精算无病生存率（DFS）分别为77%和65%。肿瘤较大、疾病复发或面神经受累的患者DFS率往往较低。对于采用每日一次与每日两次放疗分割方案治疗的患者，未观察到统计学上的显著差异。
治疗耐受性良好，严重的治疗后遗症不常见。总之，手术联合放射治疗在控制腮腺恶性肿瘤方面非常有效。
